Novartis Ag

Other

Glaxosmithkline Biologicals Sa

Irm LLC

Yefen Zou

Tom Yao-Hsiang Wu

Timothy Z Hoffman

Jianfeng Pan

Yongkai Li

Xiaoyue Zhang

Alex Cortez

Manmohan Singh

Nicholas M Valiante

Pranab Mishra

Kathy Yue

Jun Liu

Dirk Behnke

Juergen Klaus Maibaum

Qihui Jin

David Skibinski

Yun Feng Xie

Xueshi Hao

Cameron Lee

Arnaud Lacoste

Tom Yao Hsiang Wu

Tingting Mo

David A G Skibinksi

Frada Berenshteyn

Yahu Liu

Xin Qu

Jan Tchorz

Shanshan Yan

David A G Skibinski

Nicholas Valiante

Timothy Hoffman

David Ag Skibinski

The present invention is related to 6-6 Fused Bicyclic Heteroaryl Compounds of the Formula A2 or A1 and their Use as LATS Inhibitors, or a salt, stereoisomer or pharmaceutical composition thereof; wherein the variables are as defined herein. The present invention further relates to a method of LATS inhibition in a cell population using a compound of Formula A1, or a salt, stereoisomer or pharmaceutical composition thereof. The present invention further provides a method for manufacturing compounds of the invention, and its therapeutic uses. The invention further provides methods to their preparation, to their medical use, their use in the treatment and management of diseases or disorders.

6-6 fused bicyclic heteroaryl compounds and their use as LATS inhibitors

Immunopotentiators can be adsorbed to insoluble metal salts, such as aluminum salts, to modify their pharmacokinetics, pharmacodynamics, intramuscular retention time, and/or immunostimulatory effect. Immunopotentiators are modified to introduce a moiety, such as a phosphonate group, which can mediate adsorption. These modified compounds can retain or improve their in vivo immunological activity even when delivered in an adsorbed form.

Adsorption of immunopotentiators to insoluble metal salts

The invention provides a novel class of compounds, immunogenic compositions and pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with Toll-Like Receptors 2. In one aspect, the compounds are useful as adjuvants for enhancing the effectiveness of a vaccine.

Compounds and compositions as TLR2 agonists

The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with Toll-Like Receptors, including TLR7 and TLR8. In one aspect, the compounds are useful as adjuvants for enhancing the effectiveness of a vaccine (formula I) wherein: Xis N; Xis N Or CR; Xis &#x2014;CR&#x2550;CR. 

Compounds and compositions as TLR activity modulators

The invention provides a novel class of compounds viz. generally lipopeptides like Pam3CSK4, immunogenic compositions and pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with Toll-Like Receptors 2. In one aspect, the compounds are useful as adjuvants for enhancing the effectiveness a vaccine.

Compounds (cystein based lipopeptides) and compositions as TLR2 agonists used for treating infections, inflammations, respiratory diseases etc

Growing community of inventors

San Diego, CA, United States of America

Yefen Zou